Newsylist real-time news trend intelligence
▲ Peaking Health

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

India has approved Takeda's Qdenga, marking the country's first-ever approved vaccine against dengue.

7sources
8articles
5velocity
+89%since first seen
6h agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

5420Jul 21 05:29Jul 21 13:29 UTC

The brief

The Central Drugs Standard Control Organisation (DCGI) has cleared the Japanese drugmaker Takeda's vaccine, Qdenga, for use in India. The approval extends to individuals aged 4 to 60 years.

Coverage from Reuters, The Hindu, The Indian Express, NDTV, and The Times of India emphasizes the vaccine's status as the first of its kind in the country. Reports highlight the necessity of the vaccine given the challenges of immunity and the presence of four different virus strains.

Future focus remains on the specific details of effectiveness, dosage requirements, and eligibility criteria for the approved age group.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6h ago.

Quick answers

Who is eligible for the Qdenga vaccine in India?

The vaccine is approved for individuals aged 4 to 60 years.

Which company developed the vaccine?

The vaccine was developed by the Japanese drugmaker Takeda.

Why is immunity considered a challenge for dengue?

According to The Times of India, there are four different virus strains that contribute to the challenge of immunity.

Coverage (8)

People, places & organizations

Topics

Related trends